Lenalidomide as first-line and 2nd-line treatment in patients with low risk, non-deletion 5q myelodysplastic syndromes.

Trial Profile

Lenalidomide as first-line and 2nd-line treatment in patients with low risk, non-deletion 5q myelodysplastic syndromes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jan 2015

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2015 According to a Celgene Corporation media release, submission of lenalidomide in the U.S. and discussion of lenalidomide for non-deletion 5q myelodysplastic syndrome with regulatory authorities in additional geographies is expected in 2015.
    • 16 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top